Evidence map›Paper›PMID 29183158›Full record

ReviewAntioxidants & redox signaling2019

Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease.

Olga Gorelenkova Miller, John J Mieyal

Abstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. The Role ofBiomolecules · 2025
    Review
  4. HSPBiomedicines · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Secretome Analyses Identify FKBP4 as aInternational journal of molecular sciences · 2024
    Article
  10. Review
  11. Pathogens (Basel, Switzerland) · 2023
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Oxidative Stress Orchestrates MAPK and Nitric-Oxide Synthase Signal.International journal of molecular sciences · 2020
    Review
  17. Article
  18. Redox RegulationAntioxidants & redox signaling · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Olga Gorelenkova MillerDepartment of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, Ohio.
John J MieyalDepartment of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, Ohio.
Case Western Reserve University · US

Funding

Glutaredoxin, a Critical Regulator of Parkinson Disease PathogenesisR21NS085503 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., MIEYAL, JOHN J · 2013 to 2014
$434k
Enzymatic Regulation of S-Glutathionylation : Role in Apoptosis and DiseaseI01BX000290 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI MIEYAL, JOHN J · 2011 to 2012
–
BLRD VA I01 BX000290NINDS NIH HHS R21 NS085503
6 · The paper itself

Abstract

significanceGlutaredoxin (Grx)1, an evolutionarily conserved and ubiquitous enzyme, regulates redox signal transduction and protein redox homeostasis by catalyzing reversible S-glutathionylation. Grx1 plays different roles in different cell types. In Parkinson's disease (PD), Grx1 regulates apoptosis signaling in dopaminergic neurons, so that loss of Grx1 leads to increased cell death; in microglial cells, Grx1 regulates proinflammatory signaling, so that upregulation of Grx1 promotes cytokine production. Here we examine the regulatory roles of Grx1 in PD with a view toward therapeutic innovation. Recent Advances: In postmortem midbrain PD samples, Grx1 was decreased relative to controls, specifically within dopaminergic neurons. In Caenorhabditis elegans models of PD, loss of the Grx1 homologue led to exacerbation of the neurodegenerative phenotype. This effect was partially relieved by overexpression of neuroprotective DJ-1, consistent with regulation of DJ-1 content by Grx1. Increased GLRX copy number in PD patients was associated with earlier PD onset; and Grx1 levels correlated with levels of proinflammatory tumor necrosis factor-α in mouse and human brain samples. In vitro studies showed Grx1 to be upregulated on proinflammatory activation of microglia. Direct overexpression of Grx1 increased microglial activation; silencing Grx1 diminished activation. Grx1 upregulation in microglia corresponded to increased neuronal cell death in coculture. Overall, these studies identify competing roles of Grx1 in PD etiology. CRITICAL ISSUES: The dilemma regarding Grx1 as a PD therapeutic target is whether to stimulate its upregulation for neuroprotection or inhibit its proinflammatory activity. FUTURE DIRECTIONS: Further investigation is needed to understand the preponderant role of Grx1 regarding dopaminergic neuronal survival.

Indexed as

Age of OnsetAnimalsDopaminergic NeuronsDown-RegulationGene DosageGlutaredoxinsHumansMesencephalonMicrogliaParkinson DiseaseProtein Deglycase DJ-1GLRX protein, humanGlutaredoxinsPARK7 protein, humanProtein Deglycase DJ-1glutaredoxinneuroinflammationneuroprotectionParkinson's disease

Identifiers

PMID29183158
PMCPMC6391617
OpenAlexW2769820080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.